Psycho-Neuro-Endocrine-Immunological Basis of the Placebo Effect: Potential Applications beyond Pain Therapy
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | spa |
| dc.contributor.author | Ortega, Ángel | |
| dc.contributor.author | Salazar, Juan | |
| dc.contributor.author | Galban, Néstor | |
| dc.contributor.author | Rojas, Milagros | |
| dc.contributor.author | Ariza, Daniela | |
| dc.contributor.author | Chávez-Castillo, Mervin | |
| dc.contributor.author | Nava, Manuel | |
| dc.contributor.author | Riaño-Garzón, Manuel E. | |
| dc.contributor.author | Díaz-Camargo, Edgar Alexis | |
| dc.contributor.author | Medina-Ortiz, Oscar | |
| dc.contributor.author | Bermúdez, Valmore | |
| dc.date.accessioned | 2022-11-11T17:41:55Z | |
| dc.date.available | 2022-11-11T17:41:55Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | The placebo effect can be defined as the improvement of symptoms in a patient after the administration of an innocuous substance in a context that induces expectations regarding its effects. During recent years, it has been discovered that the placebo response not only has neurobiological functions on analgesia, but that it is also capable of generating effects on the immune and endocrine systems. The possible integration of changes in different systems of the organism could favor the well-being of the individuals and go hand in hand with conventional treatment for multiple diseases. In this sense, classic conditioning and setting expectations stand out as psychological mechanisms implicated in the placebo effect. Recent advances in neuroimaging studies suggest a relationship between the placebo response and the opioid, cannabinoid, and monoaminergic systems. Likewise, a possible immune response conditioned by the placebo effect has been reported. There is evidence of immune suppression conditioned through the insular cortex and the amygdala, with noradrenalin as the responsible neurotransmitter. Finally, a conditioned response in the secretion of different hormones has been determined in different studies; however, the molecular mechanisms involved are not entirely known. Beyond studies about its mechanism of action, the placebo effect has proved to be useful in the clinical setting with promising results in the management of neurological, psychiatric, and immunologic disorders. However, more research is needed to better characterize its potential use. This review integrates current knowledge about the psycho-neuro-endocrine-immune basis of the placebo effect and its possible clinical applications. | eng |
| dc.format.mimetype | eng | |
| dc.identifier.citation | Ortega, Á., Salazar, J., Galban, N., Rojas, M., Ariza, D., Chávez-Castillo, M., Nava, M., Riaño-Garzón, M. E., Díaz-Camargo, E. A., Medina-Ortiz, O., & Bermúdez, V. (2022). Psycho-Neuro-Endocrine-Immunological Basis of the Placebo Effect: Potential Applications beyond Pain Therapy. International Journal of Molecular Sciences, 23(8), 4196. https://doi.org/10.3390/ijms23084196 | eng |
| dc.identifier.doi | https://doi.org/10.3390/ijms23084196 | |
| dc.identifier.issn | 14220067 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/11295 | |
| dc.language.iso | eng | eng |
| dc.publisher | MDPI | eng |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | eng |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | International Journal of Molecular Sciences | eng |
| dc.source | Vol. 23, Isuue 8 (2022) | eng |
| dc.subject | placebo effect | eng |
| dc.subject | Psychoneuroimmunology | eng |
| dc.subject | Conditioning | eng |
| dc.title | Psycho-Neuro-Endocrine-Immunological Basis of the Placebo Effect: Potential Applications beyond Pain Therapy | eng |
| dc.type.driver | info:eu-repo/semantics/article | eng |
| dc.type.spa | Artículo científico | spa |
| dcterms.references | Jütte, R. The Early History of the Placebo. Complement. Ther. Med. 2013, 21, 94–97. | eng |
| dcterms.references | Kerr, C.E.; Milne, I.; Kaptchuk, T.J. William Cullen and a Missing Mind-Body Link in the Early History of Placebos. J. R. Soc. Med. 2008, 101, 89–92. | eng |
| dcterms.references | Tavel, M.E. The Placebo Effect: The Good, the Bad, and the Ugly. Am. J. Med. 2014, 127, 484–488. | eng |
| dcterms.references | Colagiuri, B.; Schenk, L.A.; Kessler, M.D.; Dorsey, S.G.; Colloca, L. The Placebo Effect: From Concepts to Genes. Neuroscience 2015, 307, 171–190. | eng |
| dcterms.references | Colagiuri, B.; Schenk, L.A.; Kessler, M.D.; Dorsey, S.G.; Colloca, L. The Placebo Effect: From Concepts to Genes. Neuroscience 2015, 307, 171–190. | eng |
| dcterms.references | Wager, T.D.; Atlas, L.Y. The Neuroscience of Placebo Effects: Connecting Context, Learning and Health. Nat. Rev. Neurosci. 2015, 16, 403–418. | eng |
| dcterms.references | Klinger, R.; Colloca, L.; Bingel, U.; Flor, H. Placebo Analgesia: Clinical Applications. Pain 2014, 155, 1055–1058. | eng |
| dcterms.references | Meyer, B.; Yuen, K.S.L.; Ertl, M.; Polomac, N.; Mulert, C.; Büchel, C.; Kalisch, R. Neural Mechanisms of Placebo Anxiolysis. J. Neurosci. 2015, 35, 7365–7373. | eng |
| dcterms.references | Frisaldi, E.; Carlino, E.; Zibetti, M.; Barbiani, D.; Dematteis, F.; Lanotte, M.; Lopiano, L.; Benedetti, F. The Placebo Effect on Bradykinesia in Parkinson’s Disease with and without Prior Drug Conditioning. Mov. Disord. 2017, 32, 1474–1478. | eng |
| dcterms.references | Tolusso, D.V.; Laurent, C.M.; Fullenkamp, A.M.; Tobar, D.A. Placebo Effect: Influence on Repeated Intermittent Sprint Performance on Consecutive Days. J. Strength Cond. Res. 2015, 29, 1915–1924. | eng |
| dcterms.references | Turi, Z.; Bjørkedal, E.; Gunkel, L.; Antal, A.; Paulus, W.; Mittner, M. Evidence for Cognitive Placebo and Nocebo Effects in Healthy Individuals. Sci. Rep. 2018, 8, 17443. | eng |
| dcterms.references | Benedetti, F. Placebo-Induced Improvements: How Therapeutic Rituals Affect the Patient’s Brain. J. Acupunct. Meridian Stud. 2012, 5, 97–103. | eng |
| dcterms.references | Kong, J.; Spaeth, R.; Cook, A.; Kirsch, I.; Claggett, B.; Vangel, M.; Gollub, R.L.; Smoller, J.W.; Kaptchuk, T.J. Are All Placebo Effects Equal? Placebo Pills, Sham Acupuncture, Cue Conditioning and Their Association. PLoS ONE 2013, 8, e67485. | eng |
| dcterms.references | Zheng, Y.-C.; Yuan, T.-T.; Liu, T. Is Acupuncture a Placebo Therapy? Complement. Ther. Med. 2014, 22, 724–730. | eng |
| dcterms.references | Geuter, S.; Koban, L.; Wager, T.D. The Cognitive Neuroscience of Placebo Effects: Concepts, Predictions, and Physiology. Annu. Rev. Neurosci. 2017, 40, 167–188. | eng |
| dcterms.references | Eelen, P. Classical Conditioning: Classical Yet Modern. Psychol. Belg. 2018, 58, 196–211. | eng |
| dcterms.references | Frisaldi, E.; Piedimonte, A.; Benedetti, F. Placebo and Nocebo Effects: A Complex Interplay Between Psychological Factors and Neurochemical Networks. Am. J. Clin. Hypn. 2015, 57, 267–284. | eng |
| dcterms.references | Colloca, L.; Miller, F.G. How Placebo Responses Are Formed: A Learning Perspective. Philos. Trans. R. Soc. B 2011, 366, 1859–1869. [Google Scholar] [CrossRef][Green Version] | eng |
| dcterms.references | Carlino, E.; Torta, D.M.E.; Piedimonte, A.; Frisaldi, E.; Vighetti, S.; Benedetti, F. Role of Explicit Verbal Information in Conditioned Analgesia: Explicit Verbal Information in Conditioned Analgesia. Eur. J. Pain 2015, 19, 546–553. | eng |
| dcterms.references | Ursano, A.M.; Sonnenberg, S.M.; Ursano, R.J. Physician-Patient Relationship. In Psychiatry; Tasman, A., Kay, J., Lieberman, J.A., First, M.B., Riba, M.B., Eds.; John Wiley & Sons, Ltd.: Chichester, UK, 2015; pp. 20–33. ISBN 978-1-118-75337-8. | eng |
| dcterms.references | Rabinovich, M.; Kacen, L. Transference in View of a Classical Conditioning Model. Am. J. Psychol. 2012, 125, 209–223. | eng |
| dcterms.references | Carlino, E.; Benedetti, F. Placebo and Nocebo Effects. In The Handbook of Behavioral Medicine; Mostofsky, D.I., Ed.; John Wiley & Sons, Ltd.: Oxford, UK, 2014; pp. 36–57. ISBN 978-1-118-45394-0. | eng |
| dcterms.references | Brown, W.A. Expectation, the Placebo Effect and the Response to Treatment. R. I. Med. J. 2015, 98, 19–21. | eng |
| dcterms.references | Price, D.D.; Finniss, D.G.; Benedetti, F. A Comprehensive Review of the Placebo Effect: Recent Advances and Current Thought. Annu. Rev. Psychol. 2008, 59, 565–590. | eng |
| dcterms.references | Campbell, J.N.; Meyer, R.A. Mechanisms of Neuropathic Pain. Neuron 2006, 52, 77–92. | eng |
| dcterms.references | Vachon-Presseau, E.; Berger, S.E.; Abdullah, T.B.; Huang, L.; Cecchi, G.; Griffith, J.W.; Schnitzer, T.J.; Apkarian, A.V. Brain and Psychological Determinants of Placebo Pill Response in Chronic Pain Patients. Neuroscience 2017, 9, 3397. | eng |
| dcterms.references | Wanigasekera, V.; Wartolowska, K.; Huggins, J.P.; Duff, E.P.; Vennart, W.; Whitlock, M.; Massat, N.; Pauer, L.; Rogers, P.; Hoggart, B.; et al. Disambiguating Pharmacological Mechanisms from Placebo in Neuropathic Pain Using Functional Neuroimaging. Br. J. Anaesth. 2018, 120, 299–307. | eng |
| dcterms.references | Wager, T.D.; Atlas, L.Y.; Leotti, L.A.; Rilling, J.K. Predicting Individual Differences in Placebo Analgesia: Contributions of Brain Activity during Anticipation and Pain Experience. J. Neurosci. 2011, 31, 439–452. | eng |
| dcterms.references | Xu, L.; Wan, Y.; Ma, L.; Zheng, J.; Han, B.; Liu, F.-Y.; Yi, M.; Wan, Y. A Context-Based Analgesia Model in Rats: Involvement of Prefrontal Cortex. Neurosci. Bull. 2018, 34, 1047–1057. | eng |
| dcterms.references | Hikida, T.; Morita, M.; Macpherson, T. Neural Mechanisms of the Nucleus Accumbens Circuit in Reward and Aversive Learning. Neurosci. Res. 2016, 108, 1–5. | eng |
| dcterms.references | Watanabe, M. Emotional and Motivational Functions of the Prefrontal Cortex. Brain Nerve 2016, 68, 1291–1299. | eng |
| dcterms.references | Krummenacher, P.; Candia, V.; Folkers, G.; Schedlowski, M.; Schönbächler, G. Prefrontal Cortex Modulates Placebo Analgesia. Pain 2010, 148, 368–374. | eng |
| dcterms.references | Peciña, M.; Bohnert, A.S.B.; Sikora, M.; Avery, E.T.; Langenecker, S.A.; Mickey, B.J.; Zubieta, J.-K. Association between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression. JAMA Psychiatry 2015, 72, 1087–1094. | eng |
| dcterms.references | Petrovic, P.; Dietrich, T.; Fransson, P.; Andersson, J.; Carlsson, K.; Ingvar, M. Placebo in Emotional Processing—Induced Expectations of Anxiety Relief Activate a Generalized Modulatory Network. Neuron 2005, 46, 957–969. | eng |
| dcterms.references | Duarte, D.F. Uma Breve História Do Ópio e Dos Opióides. Rev. Bras. Anestesiol. 2005, 55, 135–146. | eng |
| dcterms.references | Rosenblum, A.; Marsch, L.A.; Joseph, H.; Portenoy, R.K. Opioids and the Treatment of Chronic Pain: Controversies, Current Status, and Future Directions. Exp. Clin. Psychopharmacol. 2008, 16, 405–416. | eng |
| dcterms.references | Hughes, J.; Smith, T.W.; Kosterlitz, H.W.; Fothergill, L.A.; Morgan, B.A.; Morris, H.R. Identification of Two Related Pentapeptides from the Brain with Potent Opiate Agonist Activity. Nature 1975, 258, 577–580. | eng |
| dcterms.references | Grossman, A.; Clement-Jones, V. Opiate Receptors: Enkephalins and Endorphins. Clin. Endocrinol. Metab. 1983, 12, 31–56. | eng |
| dcterms.references | Gu, Z.-H.; Wang, B.; Kou, Z.-Z.; Bai, Y.; Chen, T.; Dong, Y.-L.; Li, H.; Li, Y.-Q. Endomorphins: Promising Endogenous Opioid Peptides for the Development of Novel Analgesics. Neurosignals 2017, 25, 98–116 | eng |
| dcterms.references | Schwarzer, C. 30 Years of Dynorphins—New Insights on Their Functions in Neuropsychiatric Diseases. Pharmacol. Ther. 2009, 123, 353–370. | eng |
| dcterms.references | Manglik, A.; Kruse, A.C.; Kobilka, T.S.; Thian, F.S.; Mathiesen, J.M.; Sunahara, R.K.; Pardo, L.; Weis, W.I.; Kobilka, B.K.; Granier, S. Crystal Structure of the Μ-Opioid Receptor Bound to a Morphinan Antagonist. Nature 2012, 485, 321–326. | eng |
| dcterms.references | Granier, S.; Manglik, A.; Kruse, A.C.; Kobilka, T.S.; Thian, F.S.; Weis, W.I.; Kobilka, B.K. Structure of the δ-Opioid Receptor Bound to Naltrindole. Nature 2012, 485, 400–404. | eng |
| dcterms.references | Wu, H.; Wacker, D.; Mileni, M.; Katritch, V.; Han, G.W.; Vardy, E.; Liu, W.; Thompson, A.A.; Huang, X.-P.; Carroll, F.I.; et al. Structure of the Human κ-Opioid Receptor in Complex with JDTic. Nature 2012, 485, 327–332. | eng |
| dcterms.references | Peng, J.; Sarkar, S.; Chang, S.L. Opioid Receptor Expression in Human Brain and Peripheral Tissues Using Absolute Quantitative Real-Time RT-PCR. Drug Alcohol Depend. 2012, 124, 223–228. | eng |
| dcterms.references | Pathan, H.; Williams, J. Basic Opioid Pharmacology: An Update. Br. J. Pain 2012, 6, 11–16. | eng |
| dcterms.references | Stein, C. Opioid Receptors. Annu. Rev. Med. 2016, 67, 433–451. | eng |
| dcterms.references | Levine, J.D.; Gordon, N.C.; Fields, H.L. The Mechanism of Placebo Analgesia. Lancet 1978, 2, 654–657. | eng |
| dcterms.references | Eippert, F.; Bingel, U.; Schoell, E.D.; Yacubian, J.; Klinger, R.; Lorenz, J.; Büchel, C. Activation of the Opioidergic Descending Pain Control System Underlies Placebo Analgesia. Neuron 2009, 63, 533–543 | eng |
| dcterms.references | Lipman, J.J.; Miller, B.E.; Mays, K.S.; Miller, M.N.; North, W.C.; Byrne, W.L. Peak B Endorphin Concentration in Cerebrospinal Fluid: Reduced in Chronic Pain Patients and Increased during the Placebo Response. Psychopharmacology 1990, 102, 112–116. | eng |
| dcterms.references | Zhang, R.-R.; Zhang, W.-C.; Wang, J.-Y.; Guo, J.-Y. The Opioid Placebo Analgesia Is Mediated Exclusively through μ-Opioid Receptor in Rat. Int. J. Neuropsychopharmacol. 2013, 16, 849–856. | eng |
| dcterms.references | Peciña, M.; Love, T.; Stohler, C.S.; Goldman, D.; Zubieta, J.-K. Effects of the Mu Opioid Receptor Polymorphism (OPRM1 A118G) on Pain Regulation, Placebo Effects and Associated Personality Trait Measures. Neuropsychopharmacology 2015, 40, 957–965. | eng |
| dcterms.references | Zubieta, J.-K. Placebo Effects Mediated by Endogenous Opioid Activity on-Opioid Receptors. J. Neurosci. 2005, 25, 7754–7762. | eng |
| dcterms.references | Scott, D.J.; Stohler, C.S.; Egnatuk, C.M.; Wang, H.; Koeppe, R.A.; Zubieta, J.-K. Placebo and Nocebo Effects Are Defined by Opposite Opioid and Dopaminergic Responses. Arch. Gen. Psychiatry 2008, 65, 220. | eng |
| dcterms.references | Zubieta, J.-K.; Stohler, C.S. Neurobiological Mechanisms of Placebo Responses. Ann. N. Y. Acad. Sci. 2009, 1156, 198–210. | eng |
| dcterms.references | Atlas, L.Y.; Wager, T.D. A Meta-Analysis of Brain Mechanisms of Placebo Analgesia: Consistent Findings and Unanswered Questions. In Placebo Handbook of Experimental Pharmacology; Benedetti, F., Enck, P., Frisaldi, E., Schedlowski, M., Eds.; Springer: Berlin/Heidelberg, Germany, 2014; Volume 225, pp. 37–69. ISBN 978-3-662-44518-1. | eng |
| dcterms.references | Eippert, F.; Finsterbusch, J.; Bingel, U.; Büchel, C. Direct Evidence for Spinal Cord Involvement in Placebo Analgesia. Science 2009, 326, 404. | eng |
| dcterms.references | Amanzio, M.; Benedetti, F. Neuropharmacological Dissection of Placebo Analgesia: Expectation-Activated Opioid Systems versus Conditioning-Activated Specific Subsystems. J. Neurosci. 1999, 19, 484–494. | eng |
| dcterms.references | Vase, L.; Robinson, M.E.; Verne, N.G.; Price, D.D. Increased Placebo Analgesia over Time in Irritable Bowel Syndrome (IBS) Patients Is Associated with Desire and Expectation but Not Endogenous Opioid Mechanisms. Pain 2005, 115, 338–347. | eng |
| dcterms.references | Guo, J.-Y.; Wang, J.-Y.; Luo, F. Dissection of Placebo Analgesia in Mice: The Conditions for Activation of Opioid and Non-Opioid Systems. J. Psychopharmacol. 2010, 24, 1561–1567. | eng |
| dcterms.references | Lee, I.-S.; Lee, B.; Park, H.-J.; Olausson, H.; Enck, P.; Chae, Y. A New Animal Model of Placebo Analgesia: Involvement of the Dopaminergic System in Reward Learning. Sci. Rep. 2015, 5, 17140. | eng |
| dcterms.references | Mackie, K. Distribution of Cannabinoid Receptors in the Central and Peripheral Nervous System. Handb. Exp. Pharmacol. 2005, 168, 299–325. | eng |
| dcterms.references | Dhopeshwarkar, A.; Mackie, K. Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold? Mol. Pharmacol. 2014, 86, 430–437. | eng |
| dcterms.references | Woodhams, S.G.; Chapman, V.; Finn, D.P.; Hohmann, A.G.; Neugebauer, V. The Cannabinoid System and Pain. Neuropharmacology 2017, 124, 105–120. | eng |
| dcterms.references | Benedetti, F.; Amanzio, M.; Rosato, R.; Blanchard, C. Nonopioid Placebo Analgesia Is Mediated by CB1 Cannabinoid Receptors. Nat. Med. 2011, 17, 1228–1230. | eng |
| dcterms.references | Peciña, M.; Martínez-Jauand, M.; Hodgkinson, C.; Stohler, C.S.; Goldman, D.; Zubieta, J.K. FAAH Selectively Influences Placebo Effects. Mol. Psychiatry 2014, 19, 385–391. | eng |
| dcterms.references | Brodermann, H.M. Pain, Pleasure and Placebo: The Cannabinoids in Reward Processing and the Perception of Pain. Ment. Health Addict. Res. 2016, 1, 59–63. | eng |
| dcterms.references | Klein, M.O.; Battagello, D.S.; Cardoso, A.R.; Hauser, D.N.; Bittencourt, J.C.; Correa, R.G. Dopamine: Functions, Signaling, and Association with Neurological Diseases. Cell Mol. Neurobiol. 2019, 39, 31–59. | eng |
| dcterms.references | Beaulieu, J.-M.; Gainetdinov, R.R. The Physiology, Signaling, and Pharmacology of Dopamine Receptors. Pharmacol. Rev. 2011, 63, 182–217. | eng |
| dcterms.references | Beaulieu, J.-M.; Espinoza, S.; Gainetdinov, R.R. Dopamine Receptors—IUPHAR Review 13: Dopamine Receptors. Br. J. Pharmacol. 2015, 172, 1–23. | eng |
| dcterms.references | Irizarry, K.J.L.; Licinio, J. An Explanation for the Placebo Effect? Science 2005, 307, 1411–1412. | eng |
| dcterms.references | Peciña, M.; Zubieta, J.-K. Molecular Mechanisms of Placebo Responses in Humans. Mol. Psychiatry 2015, 20, 416–423. | eng |
| dcterms.references | Jarcho, J.M.; Feier, N.A.; Labus, J.S.; Naliboff, B.; Smith, S.R.; Hong, J.-Y.; Colloca, L.; Tillisch, K.; Mandelkern, M.A.; Mayer, E.A.; et al. Placebo Analgesia: Self-Report Measures and Preliminary Evidence of Cortical Dopamine Release Associated with Placebo Response. NeuroImage Clin. 2016, 10, 107–114. | eng |
| dcterms.references | Kaasinen, V.; Aalto, S.; Nagren, K.; Rinne, J.O. Expectation of Caffeine Induces Dopaminergic Responses in Humans. Eur. J. Neurosci. 2004, 19, 2352–2356. | eng |
| dcterms.references | Schulz-Schaeffer, W. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson’s Disease? Biomolecules 2015, 5, 1467–1479. | eng |
| dcterms.references | De la Fuente-Fernández, R.; Ruth, T.J.; Sossi, V.; Schulzer, M.; Calne, D.B.; Stoessl, A.J. Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson’s Disease. Science 2001, 293, 1164–1166. | eng |
| dcterms.references | De la Fuente-Fernández, R.; Phillips, A.G.; Zamburlini, M.; Sossi, V.; Calne, D.B.; Ruth, T.J.; Stoessl, A.J. Dopamine Release in Human Ventral Striatum and Expectation of Reward. Behav. Brain Res. 2002, 136, 359–363. | eng |
| dcterms.references | Strafella, A.P.; Ko, J.H.; Monchi, O. Therapeutic Application of Transcranial Magnetic Stimulation in Parkinson’s Disease: The Contribution of Expectation. NeuroImage 2006, 31, 1666–1672. | eng |
| dcterms.references | Lidstone, S.C.; Schulzer, M.; Dinelle, K.; Mak, E.; Sossi, V.; Ruth, T.J.; de la Fuente-Fernández, R.; Phillips, A.G.; Stoessl, A.J. Effects of Expectation on Placebo-Induced Dopamine Release in Parkinson Disease. Arch. Gen. Psychiatry 2010, 67, 857. | eng |
| dcterms.references | Quattrone, A.; Barbagallo, G.; Cerasa, A.; Stoessl, A.J. Neurobiology of Placebo Effect in Parkinson’s Disease: What We Have Learned and Where We Are Going: Placebo Effect in PD. Mov. Disord. 2018, 33, 1213–1227. | eng |
| dcterms.references | Haour, F. Mechanisms of the Placebo Effect and of Conditioning. Neuroimmunomodulation 2005, 12, | eng |
| dcterms.references | Vinar, O. Addiction to Placebo. Am. J. Psychiatry 1978, 135, 1000. | eng |
| dcterms.references | Kessner, S.; Sprenger, C.; Wrobel, N.; Wiech, K.; Bingel, U. Effect of Oxytocin on Placebo Analgesia: A Randomized Study. JAMA 2013, 310, 1733–1735. | eng |
| dcterms.references | Skvortsova, A.; Veldhuijzen, D.S.; Van Middendorp, H.; Van den Bergh, O.; Evers, A.W.M. Enhancing Placebo Effects in Somatic Symptoms Through Oxytocin. Psychosom. Med. 2018, 80, 353–360. | eng |
| dcterms.references | Colloca, L.; Pine, D.S.; Ernst, M.; Miller, F.G.; Grillon, C. Vasopressin Boosts Placebo Analgesic Effects in Women: A Randomized Trial. Biol. Psychiatry 2016, 79, 794–802. | eng |
| dcterms.references | Boggero, I.A.; Segerstrom, S.C. Human Psychoneuroimmunology. In Encyclopedia of Mental Health; Elsevier: Amsterdam, The Netherlands, 2016; pp. 343–349. ISBN 978-0-12-397753-3 | eng |
| dcterms.references | Dhabhar, F.S.; Malarkey, W.B.; Neri, E.; McEwen, B.S. Stress-Induced Redistribution of Immune Cells—From Barracks to Boulevards to Battlefields: A Tale of Three Hormones—Curt Richter Award Winner. Psychoneuroendocrinology 2012, 37, 1345–1368. | eng |
| dcterms.references | Rohleder, N. Acute and Chronic Stress Induced Changes in Sensitivity of Peripheral Inflammatory Pathways to the Signals of Multiple Stress Systems—2011 Curt Richter Award Winner. Psychoneuroendocrinology 2012, 37, 307–316. | eng |
| dcterms.references | Morey, J.N.; Boggero, I.A.; Scott, A.B.; Segerstrom, S.C. Current Directions in Stress and Human Immune Function. Curr. Opin. Psychol. 2015, 5, 13–17. | eng |
| dcterms.references | Herkenham, M.; Kigar, S.L. Contributions of the Adaptive Immune System to Mood Regulation: Mechanisms and Pathways of Neuroimmune Interactions. Prog. Neuropsychopharmacol. Biol. Psychiatry 2017, 79, 49–57 | eng |
| dcterms.references | Bonaz, B.; Sinniger, V.; Pellissier, S. Anti-Inflammatory Properties of the Vagus Nerve: Potential Therapeutic Implications of Vagus Nerve Stimulation: Anti-Inflammatory Effect of Vagus Nerve Stimulation. J. Physiol. 2016, 594, 5781–5790. | eng |
| dcterms.references | Madden, K.S. Sympathetic Neural-Immune Interactions Regulate Hematopoiesis, Thermoregulation and Inflammation in Mammals. Dev. Comp. Immunol. 2017, 66, 92–97. | eng |
| dcterms.references | Bonaz, B.; Sinniger, V.; Pellissier, S. The Vagus Nerve in the Neuro-Immune Axis: Implications in the Pathology of the Gastrointestinal Tract. Front. Immunol. 2017, 8, 1452. | eng |
| dcterms.references | Erickson, M.A.; Banks, W.A. Neuroimmune Axes of the Blood–Brain Barriers and Blood–Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions. Pharmacol. Rev. 2018, 70, 278–314. | eng |
| dcterms.references | Quan, N. In-Depth Conversation: Spectrum and Kinetics of Neuroimmune Afferent Pathways. Brain Behav. Immun. 2014, 40, 1–8. | eng |
| dcterms.references | Prossin, A.; Koch, A.; Campbell, P.; Laumet, G.; Stohler, C.S.; Dantzer, R.; Zubieta, J.-K. Effects of Placebo Administration on Immune Mechanisms and Relationships with Central Endogenous Opioid Neurotransmission. Mol. Psychiatry 2021, in press. | eng |
| dcterms.references | Hadamitzky, M.; Sondermann, W.; Benson, S.; Schedlowski, M. Placebo Effects in the Immune System. In International Review of Neurobiology; Elsevier: Amsterdam, The Netherlands, 2018; Volume 138, pp. 39–59. ISBN 978-0-12-814325-4. | eng |
| dcterms.references | Exton, M.S.; von Hörsten, S.; Schult, M.; Vöge, J.; Strubel, T.; Donath, S.; Steinmüller, C.; Seeliger, H.; Nagel, E.; Westermann, J.; et al. Behaviorally Conditioned Immunosuppression Using Cyclosporine A: Central Nervous System Reduces IL-2 Production via Splenic Innervation. J. Neuroimmunol. 1998, 88, 182–191. | eng |
| dcterms.references | Exton, M.S.; Schult, M.; Donath, S.; Strubel, T.; Bode, U.; del Rey, A.; Westermann, J.; Schedlowski, M. Conditioned Immunosuppression Makes Subtherapeutic Cyclosporin Effective via Splenic Innervation. Am. J. Physiol. 1999, 276, R1710–R1717. | eng |
| dcterms.references | Xie, Y.; Frede, S.; Harnish, M.J.; Exton, M.S.; Schedlowski, M. Beta-Adrenoceptor-Induced Inhibition of Rat Splenocyte Proliferation: Cytokine Gene Transcription as the Target of Action. Immunobiology 2002, 206, 345–353. | eng |
| dcterms.references | Exton, M.S.; Gierse, C.; Meier, B.; Mosen, M.; Xie, Y.; Frede, S.; Goebel, M.U.; Limmroth, V.; Schedlowski, M. Behaviorally Conditioned Immunosuppression in the Rat Is Regulated via Noradrenaline and Beta-Adrenoceptors. J. Neuroimmunol. 2002, 131, 21–30. | eng |
| dcterms.references | Pacheco-López, G.; Doenlen, R.; Krügel, U.; Arnold, M.; Wirth, T.; Riether, C.; Engler, A.; Niemi, M.-B.; Christians, U.; Engler, H.; et al. Neurobehavioural Activation during Peripheral Immunosuppression. Int. J. Neuropsychopharmacol. 2013, 16, 137–149 | eng |
| dcterms.references | Hörbelt, T.; Hetze, S.; Schedlowski, M.; Lückemann, L. Die gelernte Placeboantwort im Immunsystem. Nervenarzt 2020, 91, 667–674. | eng |
| dcterms.references | Wirth, T.; Ober, K.; Prager, G.; Vogelsang, M.; Benson, S.; Witzke, O.; Kribben, A.; Engler, H.; Schedlowski, M. Repeated Recall of Learned Immunosuppression: Evidence from Rats and Men. Brain Behav. Immun. 2011, 25, 1444–1451. | eng |
| dcterms.references | Kirchhof, J.; Petrakova, L.; Brinkhoff, A.; Benson, S.; Schmidt, J.; Unteroberdörster, M.; Wilde, B.; Kaptchuk, T.J.; Witzke, O.; Schedlowski, M. Learned Immunosuppressive Placebo Responses in Renal Transplant Patients. Proc. Natl. Acad. Sci. USA 2018, 115, 4223–4227. | eng |
| dcterms.references | Lueckemann, L.; Bösche, K.; Engler, H.; Schwitalla, J.-C.; Hadamitzky, M.; Schedlowski, M. Pre-Exposure to the Unconditioned or Conditioned Stimulus Does Not Affect Learned Immunosuppression in Rats. Brain Behav. Immun. 2016, 51, 252–257. | eng |
| dcterms.references | Buske-Kirschbaum, A.; Kirschbaum, C.; Stierle, H.; Lehnert, H.; Hellhammer, D. Conditioned Increase of Natural Killer Cell Activity (NKCA) in Humans. Psychosom. Med. 1992, 54, 123–132. | eng |
| dcterms.references | Buske-Kirschbaum, A.; Kirschbaum, C.; Stierle, H.; Jabaij, L.; Hellhammer, D. Conditioned Manipulation of Natural Killer (NK) Cells in Humans Using a Discriminative Learning Protocol. Biol. Psychol. 1994, 38, 143–155 | eng |
| dcterms.references | Grigoleit, J.-S.; Kullmann, J.S.; Winkelhaus, A.; Engler, H.; Wegner, A.; Hammes, F.; Oberbeck, R.; Schedlowski, M. Single-Trial Conditioning in a Human Taste-Endotoxin Paradigm Induces Conditioned Odor Aversion but Not Cytokine Responses. Brain Behav. Immun. 2012, 26, 234–238. | eng |
| dcterms.references | Coover, G.D.; Sutton, B.R.; Heybach, J.P. Conditioning Decreases in Plasma Corticosterone Level in Rats by Paring Stimuli with Daily Feedings. J. Comp. Physiol. Psychol. 1977, 91, 716–726. | eng |
| dcterms.references | Benedetti, F.; Pollo, A.; Lopiano, L.; Lanotte, M.; Vighetti, S.; Rainero, I. Conscious Expectation and Unconscious Conditioning in Analgesic, Motor, and Hormonal Placebo/Nocebo Responses. J. Neurosci. 2003, 23, 4315–4323. | eng |
| dcterms.references | Barreto, R.E.; Volpato, G.L. Evaluating Feeding as Unconditioned Stimulus for Conditioning of an Endocrine Effect in Nile Tilapia. Physiol. Behav. 2007, 92, 867–872. | eng |
| dcterms.references | Ader, R. Conditioned Adrenocortical Steroid Elevations in the Rat. J. Comp. Physiol. Psychol. 1976, 90, 1156–1163. | eng |
| dcterms.references | Hall, G.; Stockhorst, U.; Enck, P.; Klosterhalfen, S. Overshadowing and Latent Inhibition in Nausea-Based Context Conditioning in Humans: Theoretical and Practical Implications. Q. J. Exp. Psychol. 2016, 69, 1227–1238. | eng |
| dcterms.references | Sabbioni, M.E.; Bovbjerg, D.H.; Mathew, S.; Sikes, C.; Lasley, B.; Stokes, P.E. Classically Conditioned Changes in Plasma Cortisol Levels Induced by Dexamethasone in Healthy Men. FASEB J. 1997, 11, 1291–1296. | eng |
| dcterms.references | Davis, K.W.; Cepeda-Benito, A.; Harraid, J.H.; Wellman, P.J. Plasma Corticosterone in the Rat in Response to Nicotine and Saline Injections in a Context Previously Paired or Unpaired with Nicotine. Psychopharmacology 2005, 180, 466–472. | eng |
| dcterms.references | Stockhorst, U.; Gritzmann, E.; Klopp, K.; Schottenfeld-Naor, Y.; Hubinger, A.; Berresheim, H.-W.; Steingruber, H.-J.; Gries, F.A. Classical Conditioning of Insulin Effects in Healthy Humans. Psychosom. Med. 1999, 61, 424–435. | eng |
| dcterms.references | Detke, M.J.; Brandon, S.E.; Weingarten, H.P.; Rodin, J.; Wagner, A.R. Modulation of Behavioral and Insulin Responses by Contextual Stimuli Paired with Food. Physiol. Behav. 1989, 45, 845–851. | eng |
| dcterms.references | Roozendaal, B.; Oldenburger, W.P.; Strubbe, J.H.; Koolhaas, J.M.; Bohus, B. The Central Amygdala Is Involved in the Conditioned but Not in the Meal-Induced Cephalic Insulin Response in the Rat. Neurosci. Lett. 1990, 116, 210–215. | eng |
| dcterms.references | Stockhorst, U.; Mahl, N.; Krueger, M.; Huenig, A.; Schottenfeld-Naor, Y.; Huebinger, A.; Berresheim, H.-W.; Steingrueber, H.-J.; Scherbaum, W.A. Classical Conditioning and Conditionability of Insulin and Glucose Effects in Healthy Humans. Physiol. Behav. 2004, 81, 375–388. | eng |
| dcterms.references | Stockhorst, U.; de Fries, D.; Steingrueber, H.-J.; Scherbaum, W.A. Unconditioned and Conditioned Effects of Intranasally Administered Insulin vs. Placebo in Healthy Men: A Randomised Controlled Trial. Diabetologia 2011, 54, 1502–1506. | eng |
| dcterms.references | Overduin, J.; Jansen, A. Conditioned Insulin and Blood Sugar Responses in Humans in Relation to Binge Eating. Physiol. Behav. 1997, 61, 569–575. | eng |
| dcterms.references | Onaka, T.; Yagi, K. Oxytocin Release from the Neurohypophysis after the Taste Stimuli Previously Paired with Intravenous Cholecystokinin in Anaesthetized Rats. J. Neuroendocrinol. 1998, 10, 309–316. | eng |
| dcterms.references | Tancin, V.; Kraetzl, W.-D.; Schams, D.; Bruckmaier, R.M. The Effects of Conditioning to Suckling, Milking and of Calf Presence on the Release of Oxytocin in Dairy Cows. Appl. Anim. Behav. Sci. 2001, 72, 235–246. | eng |
| dcterms.references | Graham, J.M.; Desjardins, C. Classical Conditioning: Induction of Luteinizing Hormone and Testosterone Secretion in Anticipation of Sexual Activity. Science 1980, 210, 1039–1041. | eng |
| dcterms.references | Golombek, D.A.; Chuluyan, H.E.; Kanterewicz, B.I.; Cardinali, D.P. Increased Pineal Melatonin Content Coupled to Restricted Water Availability in a Pavlovian Conditioning Paradigm in Rats. J. Neural Transm. 1994, 98, 237–246. | eng |
| dcterms.references | Keller, A.; Akintola, T.; Colloca, L. Placebo Analgesia in Rodents: Current and Future Research. Int. Rev. Neurobiol. 2018, 138, 1–15. | eng |
| dcterms.references | Annoni, M.; Miller, F.G. Placebos in Clinical Practice: An Ethical Overview. Douleur Analg. 2014, 27, 215–220 | eng |
| dcterms.references | American Medical Association. American Medical Association Code of Ethics Opinion 8.083 (2006) Placebo Use in Clinical Practice; American Medical Association: Chicago, IL, USA, 2006. | eng |
| dcterms.references | Charlesworth, J.E.G.; Petkovic, G.; Kelley, J.M.; Hunter, M.; Onakpoya, I.; Roberts, N.; Miller, F.G.; Howick, J. Effects of Placebos without Deception Compared with No Treatment: A Systematic Review and Meta-Analysis. J. Evid. Based Med. 2017, 10, 97–107. | eng |
| dcterms.references | Carvalho, C.; Caetano, J.M.; Cunha, L.; Rebouta, P.; Kaptchuk, T.J.; Kirsch, I. Open-Label Placebo Treatment in Chronic Low Back Pain: A Randomized Controlled Trial. Pain 2016, 157, 2766–2772. | eng |
| dcterms.references | Kaptchuk, T.J.; Friedlander, E.; Kelley, J.M.; Sanchez, M.N.; Kokkotou, E.; Singer, J.P.; Kowalczykowski, M.; Miller, F.G.; Kirsch, I.; Lembo, A.J. Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome. PLoS ONE 2010, 5, e15591. | eng |
| dcterms.references | Kelley, J.M.; Kaptchuk, T.J.; Cusin, C.; Lipkin, S.; Fava, M. Open-Label Placebo for Major Depressive Disorder: A Pilot Randomized Controlled Trial. Psychother. Psychosom. 2012, 81, 312–314. | eng |
| dcterms.references | Kam-Hansen, S.; Jakubowski, M.; Kelley, J.M.; Kirsch, I.; Hoaglin, D.C.; Kaptchuk, T.J.; Burstein, R. Altered Placebo and Drug Labeling Changes the Outcome of Episodic Migraine Attacks. Sci. Transl. Med. 2014, 6, 218ra5. | eng |
| dcterms.references | Krueger, G.G.; Elewski, B.; Papp, K.; Wang, A.; Zitnik, R.; Jahreis, A. Patients with Psoriasis Respond to Continuous Open-Label Etanercept Treatment after Initial Incomplete Response in a Randomized, Placebo-Controlled Trial. J. Am. Acad. Dermatol. 2006, 54, S112–S119. | eng |
| dcterms.references | Sandler, A.D.; Bodfish, J.W. Open-Label Use of Placebos in the Treatment of ADHD: A Pilot Study. Child Care Health Dev. 2008, 34, 104–110. | eng |
| dcterms.references | Jacobs, L.D.; Cookfair, D.L.; Rudick, R.A.; Herndon, R.M.; Richert, J.R.; Salazar, A.M.; Fischer, J.S.; Goodkin, D.E.; Granger, C.V.; Simon, J.H.; et al. Intramuscular Interferon Beta-1a for Disease Progression in Relapsing Multiple Sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 1996, 39, 285–294. | eng |
| dcterms.references | Faria, V.; Gingnell, M.; Hoppe, J.M.; Hjorth, O.; Alaie, I.; Frick, A.; Hultberg, S.; Wahlstedt, K.; Engman, J.; Månsson, K.N.T.; et al. Do You Believe It? Verbal Suggestions Influence the Clinical and Neural Effects of Escitalopram in Social Anxiety Disorder: A Randomized Trial. EBio Med. 2017, 24, 179–188 | eng |
| dcterms.references | Goebel, M.U.; Meykadeh, N.; Kou, W.; Schedlowski, M.; Hengge, U.R. Behavioral Conditioning of Antihistamine Effects in Patients with Allergic Rhinitis. Psychother. Psychosom. 2008, 77, 227–234. | eng |
| dcterms.references | Goebel, M.U.; Meykadeh, N.; Kou, W.; Schedlowski, M.; Hengge, U.R. Behavioral Conditioning of Antihistamine Effects in Patients with Allergic Rhinitis. Psychother. Psychosom. 2008, 77, 227–234. | eng |
| dcterms.references | Bardo, M.T.; Valone, J.M. Morphine-Conditioned Analgesia Using a Taste Cue: Dissociation of Taste Aversion and Analgesia. Psychopharmacology 1994, 114, 269–274. | eng |
| dcterms.references | Miller, J.S.; Kelly, K.S.; Neisewander, J.L.; McCoy, D.F.; Bardo, M.T. Conditioning of Morphine-Induced Taste Aversion and Analgesia. Psychopharmacology 1990, 101, 472–480. | eng |
| dcterms.references | Valone, J.M.; Randall, C.K.; Kraemer, P.J.; Bardo, M.T. Olfactory Cues and Morphine-Induced Conditioned Analgesia in Rats. Pharmacol. Biochem. Behav. 1998, 60, 115–118 | eng |
| dcterms.references | Akintola, T.; Tricou, C.; Raver, C.; Castro, A.; Colloca, L.; Keller, A. In Search of a Rodent Model of Placebo Analgesia in Chronic Orofacial Neuropathic Pain. Neurobiol. Pain 2019, 6, 100033. | eng |
| dcterms.references | McNabb, C.T.; White, M.M.; Harris, A.L.; Fuchs, P.N. The Elusive Rat Model of Conditioned Placebo Analgesia. Pain 2014, 155, 2022–2032. | eng |
| dcterms.references | Zeng, Y.; Hu, D.; Yang, W.; Hayashinaka, E.; Wada, Y.; Watanabe, Y.; Zeng, Q.; Cui, Y. A Voxel-Based Analysis of Neurobiological Mechanisms in Placebo Analgesia in Rats. Neuroimage 2018, 178, 602–612. | eng |
| dcterms.references | Mbizvo, G.K.; Nolan, S.J.; Nurmikko, T.J.; Goebel, A. Placebo Responses in Long-Standing Complex Regional Pain Syndrome: A Systematic Review and Meta-Analysis. J. Pain 2015, 16, 99–115. | eng |
| dcterms.references | Loder, E.; Goldstein, R.; Biondi, D. Placebo Effects in Oral Triptan Trials: The Scientific and Ethical Rationale for Continued Use of Placebo Controls. Cephalalgia 2005, 25, 124–131. | eng |
| dcterms.references | Meissner, K.; Fässler, M.; Rücker, G.; Kleijnen, J.; Hróbjartsson, A.; Schneider, A.; Antes, G.; Linde, K. Differential Effectiveness of Placebo Treatments: A Systematic Review of Migraine Prophylaxis. JAMA Intern. Med. 2013, 173, 1941–1951. | eng |
| dcterms.references | Cragg, J.J.; Warner, F.M.; Finnerup, N.B.; Jensen, M.P.; Mercier, C.; Richards, J.S.; Wrigley, P.; Soler, D.; Kramer, J.L.K. Meta-Analysis of Placebo Responses in Central Neuropathic Pain: Impact of Subject, Study, and Pain Characteristics. Pain 2016, 157, 530–540. | eng |
| dcterms.references | Castelnuovo, G.; Giusti, E.M.; Manzoni, G.M.; Saviola, D.; Gabrielli, S.; Lacerenza, M.; Pietrabissa, G.; Cattivelli, R.; Spatola, C.A.M.; Rossi, A.; et al. What Is the Role of the Placebo Effect for Pain Relief in Neurorehabilitation? Clinical Implications from the Italian Consensus Conference on Pain in Neurorehabilitation. Front. Neurol. 2018, 9, 310. | eng |
| dcterms.references | Cepeda, M.S.; Berlin, J.A.; Gao, C.Y.; Wiegand, F.; Wada, D.R. Placebo Response Changes Depending on the Neuropathic Pain Syndrome: Results of a Systematic Review and Meta-Analysis. Pain Med. 2012, 13, 575–595. | eng |
| dcterms.references | Häuser, W.; Sarzi-Puttini, P.; Tölle, T.R.; Wolfe, F. Placebo and Nocebo Responses in Randomised Controlled Trials of Drugs Applying for Approval for Fibromyalgia Syndrome Treatment: Systematic Review and Meta-Analysis. Clin. Exp. Rheumatol. 2012, 30, 78–87 | eng |
| dcterms.references | Macedo, A.; Baños, J.-E.; Farré, M. Placebo Response in the Prophylaxis of Migraine: A Meta-Analysis. Eur. J. Pain 2008, 12, 68–75. | eng |
| dcterms.references | Schneider, T.; Luethi, J.; Mauermann, E.; Bandschapp, O.; Ruppen, W. Pain Response to Open Label Placebo in Induced Acute Pain in Healthy Adult Males. Anesthesiology 2020, 132, 571–580. | eng |
| dcterms.references | Damien, J.; Colloca, L.; Bellei-Rodriguez, C.-É.; Marchand, S. Pain Modulation: From Conditioned Pain Modulation to Placebo and Nocebo Effects in Experimental and Clinical Pain. Int. Rev. Neurobiol. 2018, 139, 255–296. | eng |
| dcterms.references | Klinger, R.; Stuhlreyer, J.; Schwartz, M.; Schmitz, J.; Colloca, L. Clinical Use of Placebo Effects in Patients with Pain Disorders. Int. Rev. Neurobiol. 2018, 139, 107–128. | eng |
| dcterms.references | Darnall, B.D.; Colloca, L. Optimizing Placebo and Minimizing Nocebo to Reduce Pain, Catastrophizing, and Opioid Use: A Review of the Science and an Evidence-Informed Clinical Toolkit. In International Review of Neurobiology; Elsevier: Amsterdam, The Netherlands, 2018; Volume 139, pp. 129–157. ISBN 978-0-12-815416-8. | eng |
| dcterms.references | Diederich, N.J.; Goetz, C.G. The Placebo Treatments in Neurosciences: New Insights from Clinical and Neuroimaging Studies. Neurology 2008, 71, 677–684. | eng |
| dcterms.references | Kim, J.Y.; Chung, E.J.; Lee, W.Y.; Shin, H.Y.; Lee, G.H.; Choe, Y.-S.; Choi, Y.; Kim, B.J. Therapeutic Effect of Repetitive Transcranial Magnetic Stimulation in Parkinson’s Disease: Analysis of [11C] Raclopride PET Study. Mov. Disord. 2008, 23, 207–211. | eng |
| dcterms.references | Ko, J.H.; Feigin, A.; Mattis, P.J.; Tang, C.C.; Ma, Y.; Dhawan, V.; During, M.J.; Kaplitt, M.G.; Eidelberg, D. Network Modulation Following Sham Surgery in Parkinson’s Disease. J. Clin. Investig. 2014, 124, 3656–3666. | eng |
| dcterms.references | Schmidt, L.; Braun, E.K.; Wager, T.D.; Shohamy, D. Mind Matters: Placebo Enhances Reward Learning in Parkinson’s Disease. Nat. Neurosci. 2014, 17, 1793–1797. | eng |
| dcterms.references | Espay, A.J.; Norris, M.M.; Eliassen, J.C.; Dwivedi, A.; Smith, M.S.; Banks, C.; Allendorfer, J.B.; Lang, A.E.; Fleck, D.E.; Linke, M.J.; et al. Placebo Effect of Medication Cost in Parkinson Disease: A Randomized Double-Blind Study. Neurology 2015, 84, 794–802. | eng |
| dcterms.references | Shetty, N.; Friedman, J.H.; Kieburtz, K.; Marshall, F.J.; Oakes, D. The Placebo Response in Parkinson’s Disease. Parkinson Study Group. Clin. Neuropharmacol. 1999, 22, 207–212. | eng |
| dcterms.references | Diamond, S.G.; Markham, C.H.; Treciokas, L.J. Double-Blind Trial of Pergolide for Parkinson’s Disease. Neurology 1985, 35, 291–295. | eng |
| dcterms.references | Goetz, C.G.; Leurgans, S.; Raman, R.; Stebbins, G.T. Objective Changes in Motor Function during Placebo Treatment in PD. Neurology 2000, 54, 710–714. | eng |
| dcterms.references | Goetz, C.G.; Wuu, J.; McDermott, M.P.; Adler, C.H.; Fahn, S.; Freed, C.R.; Hauser, R.A.; Olanow, W.C.; Shoulson, I.; Tandon, P.K.; et al. Placebo Response in Parkinson’s Disease: Comparisons among 11 Trials Covering Medical and Surgical Interventions. Mov. Disord. 2008, 23, 690–699. | eng |
| dcterms.references | Goetz, C.G.; Leurgans, S.; Raman, R. Parkinson Study Group Placebo-Associated Improvements in Motor Function: Comparison of Subjective and Objective Sections of the UPDRS in Early Parkinson’s Disease. Mov. Disord. 2002, 17, 283–288. | eng |
| dcterms.references | Benedetti, F.; Frisaldi, E.; Carlino, E.; Giudetti, L.; Pampallona, A.; Zibetti, M.; Lanotte, M.; Lopiano, L. Teaching Neurons to Respond to Placebos. J. Physiol. 2016, 594, 5647–5660. | eng |
| dcterms.references | Dumitriu, A.; Popescu, B.O. Placebo Effects in Neurological Diseases. J. Med. Life 2010, 3, 114–121. | eng |
| dcterms.references | Oken, B.S. Placebo Effects: Clinical Aspects and Neurobiology. Brain 2008, 131, 2812–2823. | eng |
| dcterms.references | Beyenburg, S.; Stavem, K.; Schmidt, D. Placebo-Corrected Efficacy of Modern Antiepileptic Drugs for Refractory Epilepsy: Systematic Review and Meta-Analysis. Epilepsia 2010, 51, 7–26. | eng |
| dcterms.references | Marson, A.G.; Kadir, Z.A.; Chadwick, D.W. New Antiepileptic Drugs: A Systematic Review of Their Efficacy and Tolerability. BMJ 1996, 313, 1169–1174. | eng |
| dcterms.references | Guekht, A.B.; Korczyn, A.D.; Bondareva, I.B.; Gusev, E.I. Placebo Responses in Randomized Trials of Antiepileptic Drugs. Epilepsy Behav. 2010, 17, 64–69. | eng |
| dcterms.references | Brown, W.A. Placebo as a Treatment for Depression. Neuropsychopharmacology 1994, 10, 265–269. | eng |
| dcterms.references | Robinson, L.A.; Berman, J.S.; Neimeyer, R.A. Psychotherapy for the Treatment of Depression: A Comprehensive Review of Controlled Outcome Research. Psychol. Bull. 1990, 108, 30–49. | eng |
| dcterms.references | Rief, W.; Nestoriuc, Y.; Weiss, S.; Welzel, E.; Barsky, A.J.; Hofmann, S.G. Meta-Analysis of the Placebo Response in Antidepressant Trials. J. Affect. Disord. 2009, 118, 1–8. | eng |
| dcterms.references | Mavissakalian, M. The Placebo Effect in Agoraphobia. J. Nerv. Ment. Dis. 1987, 175, 95–99. | eng |
| dcterms.references | Mellergård, M.; Rosenberg, N.K. Patterns of Response during Placebo Treatment of Panic Disorder. Acta Psychiatry Scand. 1990, 81, 340–344. | eng |
| dcterms.references | Piercy, M.A.; Sramek, J.J.; Kurtz, N.M.; Cutler, N.R. Placebo Response in Anxiety Disorders. Ann. Pharmacother. 1996, 30, 1013–1019. | eng |
| dcterms.references | Huppert, J.D.; Schultz, L.T.; Foa, E.B.; Barlow, D.H.; Davidson, J.R.T.; Gorman, J.M.; Shear, M.K.; Simpson, H.B.; Woods, S.W. Differential Response to Placebo among Patients with Social Phobia, Panic Disorder, and Obsessive-Compulsive Disorder. Am. J. Psychiatry 2004, 161, 1485–1487. | eng |
| dcterms.references | Khan, A.; Kolts, R.L.; Rapaport, M.H.; Krishnan, K.R.R.; Brodhead, A.E.; Browns, W.A. Magnitude of Placebo Response and Drug-Placebo Differences across Psychiatric Disorders. Psychol. Med. 2005, 35, 743–749 | eng |
| dcterms.references | Stein, D.J.; Baldwin, D.S.; Dolberg, O.T.; Despiegel, N.; Bandelow, B. Which Factors Predict Placebo Response in Anxiety Disorders and Major Depression? An Analysis of Placebo-Controlled Studies of Escitalopram. J. Clin. Psychiatry 2006, 67, 1741–1746. | eng |
| dcterms.references | Pecknold, J.C.; Swinson, R.P.; Kuch, K.; Lewis, C.P. Alprazolam in Panic Disorder and Agoraphobia: Results from a Multicenter Trial. III. Discontinuation Effects. Arch. Gen. Psychiatry 1988, 45, 429–436. | eng |
| dcterms.references | Ballenger, J.C.; Burrows, G.D.; DuPont, R.L.; Lesser, I.M.; Noyes, R.; Pecknold, J.C.; Rifkin, A.; Swinson, R.P. Alprazolam in Panic Disorder and Agoraphobia: Results from a Multicenter Trial. I. Efficacy in Short-Term Treatment. Arch. Gen. Psychiatry 1988, 45, 413–422. | eng |
| dcterms.references | Weiss, R.D.; O’malley, S.S.; Hosking, J.D.; Locastro, J.S.; Swift, R.; COMBINE Study Research Group. Do Patients with Alcohol Dependence Respond to Placebo? Results from the COMBINE Study. J. Stud. Alcohol Drugs 2008, 69, 878–884. | eng |
| dcterms.references | Ader, R.; Cohen, N. Behaviorally Conditioned Immunosuppression and Murine Systemic Lupus Erythematosus. Science 1982, 215, 1534–1536. | eng |
| dcterms.references | Klosterhalfen, W.; Klosterhalfen, S. Pavlovian Conditioning of Immunosuppression Modifies Adjuvant Arthritis in Rats. Behav. Neurosci. 1983, 97, 663–666. | eng |
| dcterms.references | Kemeny, M.E.; Rosenwasser, L.J.; Panettieri, R.A.; Rose, R.M.; Berg-Smith, S.M.; Kline, J.N. Placebo Response in Asthma: A Robust and Objective Phenomenon. J. Allergy Clin. Immunol. 2007, 119, 1375–1381. | eng |
| dcterms.references | Kaptchuk, T.J.; Kelley, J.M.; Deykin, A.; Wayne, P.M.; Lasagna, L.C.; Epstein, I.O.; Kirsch, I.; Wechsler, M.E. Do “Placebo Responders” Exist? Contemp. Clin. Trials 2008, 29, 587–595. | eng |
| dcterms.references | Olness, K.; Ader, R. Conditioning as an Adjunct in the Pharmacotherapy of Lupus Erythematosus. J. Dev. Behav. Pediatr. 1992, 13, 124–125. | eng |
| dcterms.references | Vits, S.; Cesko, E.; Benson, S.; Rueckert, A.; Hillen, U.; Schadendorf, D.; Schedlowski, M. Cognitive Factors Mediate Placebo Responses in Patients with House Dust Mite Allergy. PLoS ONE 2013, 8, e79576. | eng |
| dcterms.references | Meissner, K.; Bingel, U.; Colloca, L.; Wager, T.D.; Watson, A.; Flaten, M.A. The Placebo Effect: Advances from Different Methodological Approaches. J. Neurosci. 2011, 31, 16117–16124. | eng |
| dcterms.references | Vits, S.; Cesko, E.; Enck, P.; Hillen, U.; Schadendorf, D.; Schedlowski, M. Behavioural Conditioning as the Mediator of Placebo Responses in the Immune System. Philos. Trans. R Soc. Lond. B Biol. Sci. 2011, 366, 1799–1807. | eng |
| dcterms.references | Schaefer, M.; Harke, R.; Denke, C. Open-Label Placebos Improve Symptoms in Allergic Rhinitis: A Randomized Controlled Trial. Psychother. Psychosom. 2016, 85, 373–374. | eng |
| dcterms.references | May, O.; Hansen, N.C. Comparison of Terbutaline, Isotonic Saline, Ambient Air and Non-Treatment in Patients with Reversible Chronic Airway Obstruction. Eur. Respir. J. 1988, 1, 527–530. | eng |
| dcterms.references | Isenberg, S.A.; Lehrer, P.M.; Hochron, S. The Effects of Suggestion on Airways of Asthmatic Subjects Breathing Room Air as a Suggested Bronchoconstrictor and Bronchodilator. J. Psychosom. Res. 1992, 36, 769–776. | eng |
| dcterms.references | Wechsler, M.E.; Kelley, J.M.; Boyd, I.O.E.; Dutile, S.; Marigowda, G.; Kirsch, I.; Israel, E.; Kaptchuk, T.J. Active Albuterol or Placebo, Sham Acupuncture, or No Intervention in Asthma. N. Engl. J. Med. 2011, 365, 119–126. | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion | eng |